ATOSSA THERAPEUTICS, INC. (ATOS) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Win.
20/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseATOS / S&P -63.31% / 15.20% |
LoseATOS / S&P ATOS unavailable / 15.00% |
LoseATOS / S&P 27.18% / 50.40% |
| 2026-Q11/3 |
LoseATOS / S&P -40.56% / -4.33% |
LoseATOS / S&P ATOS unavailable / 11.30% |
WinATOS / S&P 59.26% / 27.70% |
| 2025-Q41/3 |
LoseATOS / S&P -32.18% / 2.65% |
LoseATOS / S&P ATOS unavailable / 9.00% |
WinATOS / S&P 86.56% / 13.40% |
| 2025-Q31/3 |
LoseATOS / S&P 4.82% / 8.12% |
LoseATOS / S&P ATOS unavailable / 4.61% |
WinATOS / S&P 2045.45% / 13.45% |
| 2025-Q22/3 |
WinATOS / S&P 23.88% / 10.94% |
LoseATOS / S&P ATOS unavailable / 4.83% |
WinATOS / S&P 2142.86% / 10.63% |
| 2025-Q11/3 |
LoseATOS / S&P -28.72% / -4.27% |
LoseATOS / S&P ATOS unavailable / 4.98% |
WinATOS / S&P 1475.00% / 10.57% |
| 2024-Q41/3 |
LoseATOS / S&P -38.16% / 2.41% |
LoseATOS / S&P ATOS unavailable / 5.25% |
WinATOS / S&P 1170.83% / 6.15% |
| 2024-Q31/3 |
WinATOS / S&P 27.73% / 5.89% |
LoseATOS / S&P ATOS unavailable / 5.89% |
LoseATOS / S&P ATOS unavailable / 6.11% |
| 2024-Q20/3 |
LoseATOS / S&P -33.89% / 4.28% |
LoseATOS / S&P ATOS unavailable / 5.38% |
LoseATOS / S&P ATOS unavailable / 5.12% |
| 2024-Q11/3 |
WinATOS / S&P 104.55% / 10.56% |
LoseATOS / S&P ATOS unavailable / 5.71% |
LoseATOS / S&P ATOS unavailable / 5.59% |
| 2023-Q41/3 |
WinATOS / S&P 18.92% / 11.69% |
LoseATOS / S&P ATOS unavailable / 6.81% |
LoseATOS / S&P ATOS unavailable / 7.78% |
| 2023-Q30/3 |
LoseATOS / S&P -41.27% / -3.27% |
LoseATOS / S&P ATOS unavailable / 7.52% |
LoseATOS / S&P ATOS unavailable / -5.03% |
| 2023-Q21/3 |
WinATOS / S&P 75.00% / 8.74% |
LoseATOS / S&P ATOS unavailable / 9.50% |
LoseATOS / S&P ATOS unavailable / -8.57% |
| 2023-Q11/3 |
WinATOS / S&P 35.85% / 7.50% |
LoseATOS / S&P ATOS unavailable / 10.77% |
LoseATOS / S&P ATOS unavailable / -15.69% |
| 2022-Q40/3 |
LoseATOS / S&P -36.14% / 7.56% |
LoseATOS / S&P ATOS unavailable / 11.88% |
LoseATOS / S&P ATOS unavailable / -17.99% |
| 2022-Q30/3 |
LoseATOS / S&P -23.85% / -4.88% |
LoseATOS / S&P ATOS unavailable / 13.47% |
LoseATOS / S&P ATOS unavailable / -1.41% |
| 2022-Q21/3 |
WinATOS / S&P -12.80% / -16.10% |
LoseATOS / S&P ATOS unavailable / 13.71% |
LoseATOS / S&P ATOS unavailable / 11.04% |
| 2022-Q10/3 |
LoseATOS / S&P -21.88% / -4.60% |
LoseATOS / S&P ATOS unavailable / 15.97% |
LoseATOS / S&P ATOS unavailable / 42.23% |
| 2021-Q40/3 |
LoseATOS / S&P -50.92% / 11.03% |
LoseATOS / S&P ATOS unavailable / 15.00% |
LoseATOS / S&P ATOS unavailable / 96.40% |
| 2021-Q30/3 |
LoseATOS / S&P -48.42% / 0.58% |
LoseATOS / S&P ATOS unavailable / 10.77% |
LoseATOS / S&P ATOS unavailable / 69.42% |
| 2021-Q21/3 |
WinATOS / S&P 199.53% / 8.55% |
LoseATOS / S&P ATOS unavailable / 6.58% |
LoseATOS / S&P ATOS unavailable / 51.81% |
| 2021-Q11/3 |
WinATOS / S&P 122.11% / 6.17% |
LoseATOS / S&P ATOS unavailable / -1.06% |
LoseATOS / S&P ATOS unavailable / 7.39% |
| 2020-Q40/3 |
LoseATOS / S&P -60.74% / 12.15% |
LoseATOS / S&P ATOS unavailable / -3.72% |
LoseATOS / S&P ATOS unavailable / -33.42% |
| 2020-Q30/3 |
LoseATOS / S&P -36.32% / 8.93% |
LoseATOS / S&P ATOS unavailable / -2.04% |
LoseATOS / S&P ATOS unavailable / -27.10% |
| 2020-Q21/3 |
WinATOS / S&P 185.71% / 20.54% |
LoseATOS / S&P ATOS unavailable / -0.46% |
LoseATOS / S&P ATOS unavailable / -27.11% |
| 2020-Q11/3 |
WinATOS / S&P -15.29% / -19.60% |
LoseATOS / S&P ATOS unavailable / 3.47% |
LoseATOS / S&P ATOS unavailable / -14.75% |
| 2019-Q40/3 |
LoseATOS / S&P -19.90% / 9.07% |
LoseATOS / S&P ATOS unavailable / 5.36% |
LoseATOS / S&P ATOS unavailable / 2.99% |
| 2019-Q30/3 |
LoseATOS / S&P -23.14% / 1.70% |
LoseATOS / S&P ATOS unavailable / 5.02% |
LoseATOS / S&P ATOS unavailable / 0.21% |
| 2019-Q20/3 |
LoseATOS / S&P -27.56% / 4.30% |
LoseATOS / S&P ATOS unavailable / 6.64% |
LoseATOS / S&P ATOS unavailable / 8.65% |
| 2019-Q11/3 |
WinATOS / S&P 245.10% / 13.65% |
LoseATOS / S&P ATOS unavailable / 8.12% |
LoseATOS / S&P ATOS unavailable / 14.29% |
| 2018-Q40/3 |
LoseATOS / S&P -41.71% / -13.52% |
LoseATOS / S&P ATOS unavailable / 9.05% |
LoseATOS / S&P ATOS unavailable / 18.23% |
| 2018-Q30/3 |
LoseATOS / S&P -20.45% / 7.71% |
LoseATOS / S&P ATOS unavailable / 10.21% |
LoseATOS / S&P ATOS unavailable / 19.06% |
| 2018-Q20/3 |
LoseATOS / S&P -59.26% / 3.43% |
LoseATOS / S&P ATOS unavailable / 9.03% |
LoseATOS / S&P ATOS unavailable / 14.46% |
| 2018-Q11/3 |
WinATOS / S&P 73.08% / -0.76% |
LoseATOS / S&P ATOS unavailable / 7.68% |
LoseATOS / S&P ATOS unavailable / 12.46% |
| 2017-Q40/3 |
LoseATOS / S&P -50.94% / 6.64% |
LoseATOS / S&P ATOS unavailable / 7.03% |
LoseATOS / S&P ATOS unavailable / 13.82% |
| 2017-Q31/3 |
WinATOS / S&P 6.00% / 4.48% |
LoseATOS / S&P ATOS unavailable / 5.68% |
LoseATOS / S&P ATOS unavailable / 17.57% |
| 2017-Q20/3 |
LoseATOS / S&P -34.21% / 3.09% |
LoseATOS / S&P ATOS unavailable / 4.83% |
LoseATOS / S&P ATOS unavailable / 17.74% |
| 2017-Q10/3 |
LoseATOS / S&P -46.10% / 6.07% |
LoseATOS / S&P ATOS unavailable / 3.67% |
LoseATOS / S&P ATOS unavailable / 13.32% |
| 2016-Q40/3 |
LoseATOS / S&P -32.86% / 3.82% |
LoseATOS / S&P ATOS unavailable / 2.09% |
LoseATOS / S&P ATOS unavailable / 7.05% |
| 2016-Q30/3 |
LoseATOS / S&P -50.00% / 3.85% |
LoseATOS / S&P -35.20% / 0.20% |
LoseATOS / S&P ATOS unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ATOS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -76.84% | 20.78% |
| Annualized return | -76.84% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | ATOS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -95.32% | 83.14% |
| Annualized return | -45.79% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | ATOS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.39% | 319.30% |
| Annualized return | -39.96% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |